Cyclin T1 (D1B6G) Rabbit mAb 81464S from Cell Signaling Technology

Published Figures

Register or Sign In to View Figures.

Nature Communications
December 01 2022

Fig 1: Hit validation using multiplexed gRNA.A Schematic of the multiplex gRNA approach for gene knock out in primary CD4+ T cells. B Bar charts depicting percent HIV-infected cells post challenge upon knockout with individual gRNA 1 through 4 versus a multiplexed pool of gRNAs 1 through 4 (average of technical triplicates ±SD). Western blots below depict protein depletion for each targeted gene. Three independent loci were targeted: CCNT1 (left), CYPA (middle), and LEDGF (right). C Box-and-whisker plot of the average percent of live CD4 + T cells in each well four days after electroporation with multiplexed gRNA; center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; black points, outliers. Outlier points are considered toxic and are labeled by targeted gene name. D S-curve plot of the log2 fold change in infection relative to the plate median at day 5 for each multiplexed gRNA, averaged across all 3 donors ±SD. The dashed black line indicates the median; the dashed gray lines represent the nontargeting range. Dots are colored by toxicity and by phenotype in the original screen as indicated. E Box-and-whisker plot of the distribution of log2-normalized HIV-infection rates for dependency factors (n = 52) versus restriction factors (n = 21) versus essential genes (n = 13) at day 5. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; p-value reflects a two-sided Wilcoxon rank-sum test comparing dependency factors and restriction factors each measured in three biologically independent replicates. F Line chart of log2-normalized HIV-infection rates over time for each validated hit (two-sided Wilcoxon rank-sum test, p-value < 0.1 at multiple timepoints). Restriction factors are shown above and dependency factors shown below with relevant controls. Genes with significant differences at day 3 are coded “early” and sorted by magnitude of effect; genes with significant differences at only days 5 or 7 are coded as “late”. G Log2-normalized HIV-infection rates at day 5 after multicycle replication versus at day 3 after single-cycle replication in the presence of Saquinavir. The linear regression line with 95% confidence interval is shown in gray.
Register or Sign In to View Figures.

eLife
November 25 2021

Fig 2: Phosphorylation of Thr143 and Thr149 stabilizes the interface between CycT1 and CDK9.(A) Model of P-TEFb where CycT1 is phosphorylated at Thr143 and Thr149. The model was created by adding phosphates to Thr143 and Thr149 in the published crystal structure of P-TEFb (PDB ID 3MI9), followed by energy minimization and molecular dynamics (MD) simulations. Residues predicted to interact with Thr143 and Thr149 are Gln73 in CycT1 and Lys68 in CDK9, respectively. (B) Gln73 is targeted by phosphorylated Thr143 in CycT1. WT CycT1(280) or mutant CycT1(280)Q73A proteins and CDK9 were coexpressed in the presence of bortezomib (+/- signs on top) in 293T cells. Co-IPs with CDK9 are presented in panels 1 and 2. Panels 3 and 4 contain input levels of CycT1 and CDK9 proteins. (C) Lys68 in CDK9 is targeted by phosphorylated Thr149 in CycT1. WT CDK9 or mutant CDK9K68A proteins and CycT1(280) were coexpressed in the presence of bortezomib (+/- signs on top) in 293T cells. Co-IPs with CDK9 are presented in panels 1 and 2. Panels 3 and 4 contain input levels of CycT1 and CDK9 proteins. (D) Mutations of K68A in CDK9 and Q73A in CycT1 attenuate cooperatively the binding between CycT1 and CDK9, equivalently to the mutant CycT1TT143149AA protein. WT CycT1(280) or mutant CycT1(280)Q73A proteins and WT CDK9 or mutant CDK9K68A proteins were coexpressed in the presence of bortezomib (+/- signs on top) in 293T cells. Co-IPs with CDK9 are presented in panels 1 and 2. Panels 3 and 4 contain input levels of CycT1 and CDK9 proteins.
Register or Sign In to View Figures.

Nucleic acids research
May 20 2022

Fig 3: Free CycT1 proteins are unstable but stabilized by proteasomal inhibitors in cells. (A) Levels of endogenous CycT1 proteins in resting CD4 + T cells are increased by proteasomal inhibitors without mRNA induction and cell activation. Resting CD4 + T cells were untreated (lane 1) or treated with 100 nM bortezomib (lane 2) or PMA/PHA (lane 3) for 24 h before cell lysis. Levels of CycT1 (panel 1), CDK9 (panel 2), and the loading control actin (panel 3) proteins were detected with indicated antibodies, respectively, by WB. Relative mRNA levels of CycT1 in bortezomib or PMA/PHA treated cells are presented in the middle bar graph as -fold change above levels of untreated cells (white bars, set as ‘1’). Error bars represent standard error of average (n = 3). Percentage of CD69 + cells in CD4 + T cells with indicated treatment are presented in the bottom table by flow cytometry with PE-conjugated anti-CD69 antibodies. These and subsequent WBs are representative of at least 3 independent experiments. The quantification of all WBs is presented in the Results section as fold-changes. (B) Graphic representation of mutant CycT1 proteins that do not interact with CDK9. Top diagram is a schematic presentation of the WT and mutant CycT1 proteins used in this study. WT CycT1 protein contains 726 residues, in which two cyclin boxes are found the N-terminal region (30–248) and a PEST motif is located at its C-terminus (709–726). The mutant CycT1 protein (CycT14MUT) contains four substitutions, E137D, T143A, T149A and T155A. CycT1(708) and CycT14MUT(708) represent two truncated proteins lacking the PEST motif. WT or indicated mutant CycT1 and CDK9 proteins were expressed in 293T cells treated with bortezomib and co-IPed with CDK9 by anti-Flag antibodies (bottom panels 1 and 2). Bottom panels 3 and 4 indicate input levels of CycT1 and CDK9 proteins. (C) Mutant CycT1 proteins that do not bind to CDK9 are degraded via the proteasome. WT CycT1 or two indicated mutant CycT1 proteins were expressed in 293T cells, which were untreated (lanes 1, 5, and 9) or treated with 2 μM MG132 (lanes 2, 6, and 10), bortezomib (lanes 4, 8, and 12), 10 μM MLN4924 (lanes 3, 7, and 11) before cell lysis. Levels of CycT1 (panel 1), CDK9 (panel 2) and the loading control actin (panel 3) proteins were detected with indicated antibodies, respectively, by WB. (D) C-terminally truncated mutant CycT1 proteins are unstable. WT CycT1 or five indicated mutant CycT1 proteins (CycT14MUT, CycT14MUT(580), CycT14MUT(480), CycT14MUT(380) and CycT14MUT(280)) were expressed in 293T cells in the presence of 2 μM bortezomib (lanes 2, 4, 6, 8, 10 and 12) or not (lanes 1, 3, 5, 7, 9 and 11) before cell lysis. Levels of CycT1 (panel 1) and the loading control actin (panel 2) proteins were detected with indicated antibodies, respectively, by WB. (E) Mutant CycT14MUT(280) proteins are degraded via proteasomal pathways. WT CycT1(280) (left panels) or mutant CycT14MUT(280) (right panels) proteins were expressed in 293T cells, which were untreated (lanes 1) or treated with 2 μM MG132 (lanes 2), bortezomib (lanes 4), 10 μM MLN4924 (lanes 3) before cell lysis. Levels of CycT1 (panels 1) and the loading control actin (panels 2) proteins were detected with indicated antibodies, respectively, by WB.
Register or Sign In to View Figures.

Nucleic acids research
May 20 2022

Fig 4: Siah1 and Siah2 preferentially interact with free CycT1. (A) Siah1 preferentially interacts with free CycT1 protein. DN Siah1C75S proteins were co-expressed with WT CycT1 or mutant CycT14MUT proteins in the presence of bortezomib in 293T cells, followed by co-IPs with CycT1 (anti-HA antibodies) (panels 1 and 2), or with Siah1 (anti-Flag antibodies) (panels 5 and 6). Panels 3 and 4 indicate input levels of CycT1 and Siah1 proteins. (B) Siah1 preferentially interacts with free CycT1(280) protein. DN Siah1C75S proteins were co-expressed with WT CycT1(280) or mutant CycT14MUT(280) proteins in the presence of bortezomib in 293T cells, followed by co-IPs with CycT1 (anti-HA antibodies) (panels 1 and 2), or with Siah1 (anti-Flag antibodies) (panels 5 and 6). Panels 3 and 4 indicate input levels of CycT1 and Siah1 proteins. (C) Siah2 preferentially interacts with free CycT1 protein. WT Siah2 proteins were co-expressed with WT CycT1 or mutant CycT14MUT proteins in the presence of bortezomib in 293T cells, followed by co-IPs with CycT1 (anti-HA antibodies) (panels 1 and 2), or with Siah2 (anti-Flag antibodies) (panels 5 and 6). Panels 3 and 4 indicate input levels of CycT1 and Siah2 proteins. (D) Siah2 preferentially interacts with free CycT1(280) protein. WT Siah2 proteins were co-expressed with WT CycT1(280) or mutant CycT14MUT(280) proteins in the presence of bortezomib in 293T cells, followed by co-IPs with CycT1 (anti-HA antibodies) (panels 1 and 2), or with Siah2 (anti-Flag antibodies) (panels 5 and 6). Panels 3 and 4 indicate input levels of CycT1 and Siah2 proteins.
Register or Sign In to View Figures.

Nucleic acids research
May 20 2022

Fig 5: Knockdown of Siah2 increases levels of free CycT1 in 293T cells and inhibition of Siah1/2 stabilizes CycT1 in primary T cells. (A) Knockdown of Siah2 stabilizes free CycT1 in 293T cells. 293T cells were transfected with scrambled shRNA (lane 1) or mixed shRNA targeting Siah2 (lane 2). 48 h after transfection, WT CycT1 or mutant CycT14MUT proteins were expressed by transient transfection for another 48 h before cell lysis. Levels of Siah2 (panel 1), CycT1 (panels 3 and 5) and the loading control actin (panels 2, 4 and 6) proteins were detected with indicated antibodies, respectively, by WB. (B) Ectopic expression of PHYL(130) stabilizes CycT1 in primary CD4 + T cells. Top diagram presents the experimental scheme. Primary T cells collected at days 3 and 7 (bottom right panels, lanes 1 and 2) were lysed and subjected to WB. Levels of CycT1 (panel 1), Siah1 (panel 2), Siah2 (panel 3) and the loading control actin (panel 4) proteins were detected with indicated antibodies, respectively. Primary T cells without electroporation (right panels, lane 1) and those electroporated with the empty plasmid vector (right panels, lane 2) or plasmids containing PHYL(130) fragments (right panels, lane 3) were collected at day 7, and cell lysates were subjected to WB. Levels of CycT1 (panel 1), PHYL (panel 2) and the loading control actin (panel 3) proteins were detected with indicated antibodies, respectively.

Be the first to write a review!

Citations:

(31)

Figures:

$339.00 Inquire

from
Cell Signaling Technology for
Cyclin T1 (D1B6G) Rabbit mAb

The Cyclin T1 (D1B6G) Rabbit mAb Antibody from Cell Signaling Technology is a Rabbit Monoclonal antibody to CCNT1. This antibody recognizes Homo Sapiens, Human, Mouse, Rat, and Non-Human Primate antigen. The Cyclin T1 (D1B6G) Rabbit mAb Antibody has been shown to work in the following applications: Precipitation, Assay, ChIP, Immunoprecipitation, Western Blot, and Other.

Description

Cyclin T1 (D1B6G) Rabbit mAb recognizes endogenous levels of total cyclin T1 protein

Product Specs
ItemCyclin T1 (D1B6G) Rabbit mAb
CompanyCell Signaling Technology
Price $339.00 Inquire
Catalog Number81464S
Molecular Weight81
Research AreaChromatin Regulation / Nuclear Function
ReactivityHu, Ms, Rt, Mk
ClonalityMonoclonal
NCBI Gene AliasesCCNT, CYCT1, HIVE1
NCBI Full Gene Namecyclin T1
ApplicationsWB, IP, ChIP
HostRabbit
IsotypeIgG
TargetCYCT1/cyclin T1
Quantity100 µl

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Discovery of a First-in-Class Murine Double Minute 2-Recruiting Positive Transcription Elongation Factor B PROTAC Degrader With Selective Antitumor ActivityMedComm (2020)April 9, 2026Xian Guan, Long Xie, Hanjun Guo, Lin Ma, Jiawei Zhou, Lisong Luo, Hao Yang, Yuanfang Wu, Jiangyu Liu, Yue Wang, et al.(Cell Signaling Technology, 2316), CDK9 (Santa Cruz, sc‐13130), Cyclin T1 (Cell Signaling Technology, 81464), Cyclin T2 (Santa Cruz, sc‐81243), p53 (Santa Cruz, sc‐126), p21 (Cell Signaling Technology, 2947),

(2) Dinaciclib improves treatment response in chemoresistant hepatoblastomaScientific ReportsDecember 5, 2025Brian T. Hickner, Andres F. Espinoza, Rohit K. Srivastava, Roma H. Patel, Priyanka Rao, Nicholas A. O’Brien, Kalyani R. Patel, Andrew A. Badachhape, Abhishek Kona, Dolores H. López-Terrada, et al.phopsho-RNA pol-II (S2) (cat. no. 91115,Thermo Fisher Scientific, Waltham, MA, USA), cyclin T1 (cat. no. 81464 Cell Signaling, Danvers, MA, USA), and PARP (cat. no. 9532 Cell Signaling, Danvers, MA, USA). The membranes

(3) Aryl hydrocarbon receptor facilitates HSV-1 lytic infection by enhancing viral gene transcription and receptor expressionFrontiers in Cellular and Infection MicrobiologyJune 25, 2025Pu Huang, Xiaohong Pan, Hongli Chen, Mengyue Lei, Ying Ma, Xiaomei Guo, Jiaxin Xie, Jixiong Li, Jing Sun, Yunzhang Hu, et al.used: anti-ICP5 (1:500, Ab6508, Abcam), anti-AhR (1:500, GTX129013, GeneTex), anti-Cyclin T1 (1:200, #81464, Cell Signaling), anti-RNA Pol II (2ug/ml, 91151, Active Motif), anti-VP16 (1:500, ab110226, Abcam),

(4) HIV-1 Nef activates proviral DNA transcription by recruiting Src kinase to phosphorylate host protein Nef-associated factor 1 to compromise its viral restrictive functionJournal of VirologyMay 20, 2025Tian-Jiao Fan, Chengzuo Xie, Lisha Li, Xia Jin, Jie Cui, Jian-Hua Wangchromatin DNA was used as the input. Nuclear extracts were incubated with antibodies against Cyclin T1 (81464; Cell Signaling Technology) or rabbit IgG (2729, Cell Signaling Technology) at 4°C overnight. Protein

(5) Ectopic expression of testis-specific transcription elongation factor in driving cancerSci AdvMarch 14, 2025Bin Zheng, Marta Iwanaszko, Shimaa Hassan AbdelAziz Soliman, Yukitomo Ishi, Sarah Gold, Ruxuan Qiu, Benjamin Charles Howard, Madhurima Das, Zibo Zhao, Rintaro Hashizume, et al.for Western blot. BRD4 (#13440), BRD2 (#5848), β-actin (#3700), CDK9 (#2316), BRD3 (#94032), and cyclin T1 (#81464) antibodies were purchased from Cell Signaling Technology. GFP antibody (#sc-9996) was purchased from

(6) Promoter-proximal RNA polymerase II termination regulates transcription during human cell type transitionNature Structural & Molecular BiologyFebruary 11, 2025Kseniia Lysakovskaia, Arjun Devadas, Björn Schwalb, Michael Lidschreiber, Patrick Cramermanufacturer’s instructions. The following antibodies were used: anti-cyclin T1 antibody (Cell Signaling, 81464) in the amount of 12.5 µl per sample, anti-CDK9 antibody (Abcam, ab239364) in the amount of 7.9 µg per

(7) TurboCas: A method for locus-specific labeling of genomic regions and isolating their associated protein interactomeMolecular CellDecember 19, 2024Bercin K. Cenik, Yuki Aoi, Marta Iwanaszko, Benjamin C. Howard, Marc A. Morgan, Grant D. Andersen, Elizabeth T. Bartom, Ali ShilatifardRabbit anti-FBP3 Antibody Affinity Purified,Bethyl,"CAT# A303-012A, RRID# AB_10750477" Cyclin T1 (D1B6G) Rabbit mAb,Cell Signaling Technologies,"CAT# 81464, RRID# AB_2799973" Rpb1 CTD (4H8) Mouse mAb,Cell Signaling Technologies,"CAT# 2629, RRID# AB_2167468" Rpb1 NTD (D8L4Y) Rabbit mAb

(8) The PNUTS phosphatase complex controls transcription pause releaseMolecular CellDecember 19, 2024Jessica R. Kelley, Emilia Dimitrova, Maciej Maciuszek, Hieu T. Nguyen, Aleksander T. Szczurek, Amy L. Hughes, Neil P. Blackledge, Arminja N. Kettenbach, Robert J. Klose13440 TFIIS (TCEA1),Abcam,Cat# ab185947 INTS11,Bethyl,Cat# A301-274A Cyclin T1,Cell Signaling,Cat# 81464 BRD4 (pan),Cell Signaling,Cat# 83375 HEXIM1,Proteintech,Cat# 15676-1-AP HRP-Conjugated Anti-Rabbit

(9) Transactivation of the novel 5’ cis-acting element of mouse mammary tumor virus (MMTV) by human retroviral transactivators Tat and TaxCommunications BiologyNovember 16, 2024Thanumol Abdul Khader, Waqar Ahmad, Shaima Akhlaq, Neena Gopinathan Panicker, Bushra Gull, Jasmin Baby, Tahir A. Rizvi, Farah Mustafaspecific antibody (anti-Cyclin T1 rabbit mAb clone D1B6G from Cell Signaling Technology, USA (Cat. No. 81464; Lot No. 1)) and anti-RNA polymerase II RBP1 clone 8WG16 from BioLegend, USA (Cat. No. 664906; (Lot

(10) HIV-1 Transcription Inhibition Using Small RNA-Binding MoleculesPharmaceuticals (Basel)December 25, 2023Pooja Khatkar, Gifty Mensah, Shangbo Ning, Maria Cowen, Yuriy Kim, Anastasia Williams, Fardokht A. Abulwerdi, Yunjie Zhao, Chen Zeng, Stuart F. J. Le Grice, et al.1:1000), α-HEXIM1 (Cat: 12604; Cell Signaling Technology, Danvers, MA, USA, 1:1000), α-Cyclin T1 (Cat: 81464, Cell signaling Technology, 1:1000), α-Cdk9 (Cat: 2316, Cell signaling Technology, 1:1000) and β-actin

(11) Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulationMolecular CellAugust 1, 2023Bin Zheng, Sarah Ruth Gold, Marta Iwanaszko, Benjamin Charles Howard, Lu Wang, Ali Shilatifardminutes. BRD4 (#13440), β-Actin (#3700), V5-Tag (#13202), HA-Tag (#3724S), CDK9 (#2316), and Cyclin T1 (#81464) antibodies were purchased from Cell Signaling Technology. Tubulin (#E7) antibody was obtained from

(12) A conditional RNA Pol II mono-promoter drives HIV-inducible, CRISPR-mediated cyclin T1 suppression and HIV inhibitionMolecular Therapy - Nucleic AcidsJune 13, 2023Srinivasan Chinnapaiyan, Maria-Jose Santiago, Kingshuk Panda, Md. Sohanur Rahman, Jessica Alluin, John Rossi, Hoshang J. UnwallaCRISPR-Cas9 (1:1,000; Thermo Fisher Scientific, cat #MA1-202), cyclin T1 (1:1,000; Cell Signaling, cat #81464), and α-tubulin (1:1,000; Cell Signaling, cat #2125), with 5% blocking solution. After incubation, the

(13) A functional map of HIV-host interactions in primary human T cellsNature CommunicationsDecember 1, 2022Joseph Hiatt, Judd F. Hultquist, Michael J. McGregor, Mehdi Bouhaddou, Ryan T. Leenay, Lacy M. Simons, Janet M. Young, Paige Haas, Theodore L. Roth, Victoria Tobin, et al.Cell Signaling Technologies, Cat. No. 2088 S), CCNT1 (1:1000 dilution, clone D1B6G, Cell Signaling Technologies, Cat. No. 81464 S), and CYPA (1:12000 dilution, polyclonal, Cell Signaling Technologies, Cat. No. 2175 S) levels were

(14) DDB1 prepares brown adipocytes for cold-induced thermogenesisLife MetabolismNovember 3, 2022Xu Wang, Shen-Ying Liu, Guo-Sheng Hu, Hao-Yan Wang, Guo-Liang Zhang, Xiang Cen, Si-Ting Xiang, Wen Liu, Peng Li, Haobin Ye, et al.Proteintech, 11424-1-AP), anti-PGC1a (1:1000, Proteintech, 66369-1-Ig), anti-CyclinT1 (1:1000, CST, 81464), anti-CDK9 (1:1000, Santa Cruz, sc-13130), anti-RNA Polymerase II (1:1000, Bethyl, A300-653A), anti-GAPDH

(15) Heterogeneity of Latency Establishment in the Different Human CD4 ⁺ T Cell Subsets Stimulated with IL-15Journal of VirologyMay 25, 2022Giacomo M. Butta et al.(Cell Signaling Technology; catalog no. 2549), anti-cyclin T1 (Cell Signaling Technology; catalog no. 81464), and anti-GAPDH (Cell Signaling Technology; catalog no. 2118). RNA isolation and quantitative real-time PCR

(16) P-TEFb is degraded by Siah1/2 in quiescent cellsNucleic acids researchMay 20, 2022Huang F, Feng Y, Peterlin BM, Fujinaga K.,Santa Cruz Biotechnology,sc-376646,"WB, 1:200; IP, 4 μg per test" Antibody,CycT1 (D1B6G) (rabbit monoclonal),Cell Signaling Technology,81464S,"WB, 1:1000" Antibody,CDK9 (EPR22956-37) (rabbit polyclonal),Abcam,ab239364,"WB, 1:1000; IP, 4 μg per

(17) A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growthJournal of hematology & oncologyApril 8, 2022Li X, Yao Y, Wu F, Song Y.(Novusbio #NB100-1565), DOT1L (Cell signaling #77087), AFF4 (Abcam #ab103586), Cyclin T1 (Cell signaling #81464), H3K79me2 (Cell signaling #5427), H3K79me1 (Cell signaling #9398), Histone H3 (Cell signaling #4499),

(18) Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52iScienceJanuary 21, 2022Dajiang Li, Morgan G. Dewey, Li Wang, Shane D. Falcinelli, Lilly M. Wong, Yuyang Tang, Edward P. Browne, Xian Chen, Nancie M. Archin, David M. Margolis, et al.T1,Cell signaling,Cat#3017 anti-RelB,Cell signaling,Cat#10544 anti-AceS1 (ACSS2),Cell signaling,Cat#81464 anti-β-TrCP,Cell signaling,Cat#11984 anti-β-actin,Cell signaling,Cat#4970 anti-Caspase-3,Cell signaling,Cat#9662 normal rabbit IgG

(19) HRas and Myc synergistically induce cell cycle progression and apoptosis of murine cardiomyocytesFrontiers in cardiovascular medicineJanuary 1, 2022Boikova A, Bywater MJ, Quaife-Ryan GA, Straube J, Thompson L, Ascanelli C, Littlewood TD, Evan GI, Hudson JE, Wilson CH.(C12F7; Cell Signaling Technology, 2316, used at 1:1,000), Cyclin T1 (D1B6G; Cell Signaling Technology, 81464, used at 1:1,000), p-ERK is phospho-p44/42 MAPK (Thr202/Tyr204, Cell Signaling Technology, 9101, used

(20) Reversible phosphorylation of cyclin T1 promotes assembly and stability of P-TEFbeLifeNovember 25, 2021Huang F, Nguyen TT, Echeverria I, Rakesh R, Cary DC, Paculova H, Sali A, Weiss A, Peterlin BM, Fujinaga K.polyclonal),Sigma-Aldrich,F7425,WB (1:1000);IP 4 μg per test Antibody,CycT1 (D1B6G) (rabbit monoclonal),Cell Signaling Technology,81464S,WB (1:1000) Antibody,β-Actin (13E5) (rabbit monoclonal),Cell Signaling Technology,4970S,WB (1:5000) Antibody,Phospho-threonine

Be the First to Write a Review!

Nature Communications

eLife

Nucleic acids research

Nucleic acids research

Nucleic acids research

Cyclin T1 (D1B6G) Rabbit mAb from Cell Signaling Technology

Description

Cell Signaling Technology

Citations (31)

Reviews

Cyclin T1 (D1B6G) Rabbit mAb from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map